Dr. M.C. Bodde

Dr. M (Mathijs) C. Bodde is in 2018 gestart met de opleiding tot cardioloog aan het Leids Universitair Medisch Centrum.

In 2020 promoveerde hij op het onderwerp: “Optimization of secondary prevention and risk stratification in patients with coronary heart disease”.

Dit deed hij onder begeleiding van promotor prof. dr. J.W Jukema en prof. dr. M.J. Schalij. Het promotie onderzoek heeft zich specifiek gericht op risicostraficatie en behandeling van patiënten na een acuut hartinfarct.

Dr. Bodde zal zijn opleiding tot cardioloog in 2025 afronden.

Top-cited publications

50 times cited (±9/year) Source: EuropePMC

Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation, Volume 25, Issue 4, 1 1 2017, Pages 231-242 Pathophysiology and treatment of atherosclerosis : Current view and future perspective on lipoprotein modification treatment. Bergheanu SC, Bodde MC, Jukema JW. Abstract


16 times cited (±2/year) Source: EuropePMC

Atherosclerosis, Volume 227, Issue 1, 24 4 2012, Pages 95-99 Determinants of calcification growth in atherosclerotic carotid arteries; a serial multi-detector CT angiography study. van Gils MJ, Bodde MC, Cremers LG, Dippel DW, van der Lugt A. Abstract


9 times cited (±2/year) Source: EuropePMC

Clinical research in cardiology : official journal of the German Cardiac Society, Volume 108, Issue 5, 8 2 2018, Pages 520-538 Apolipoproteins A1, B, and apoB/apoA1 ratio are associated with first ST-segment elevation myocardial infarction but not with recurrent events during long-term follow-up. Bodde MC, Hermans MPJ, Jukema JW, Schalij MJ, Lijfering WM, Rosendaal FR, Romijn FPHTM, Ruhaak LR, van der Laarse A, Cobbaert CM. Abstract


Most recent publications

01 Nov 2019

Netherlands heart journal : monthly journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation, Volume 27, Issue 11, 1 1 2019, Pages 550-558 Myocardial infarction patients referred to the primary care physician after 1‑year treatment according to a guideline-based protocol have a good prognosis. Bodde MC, van Hattem NE, Abou R, Mertens BJA, van Duijn HJ, Numans ME, Bax JJ, Schalij MJ, Jukema JW. Abstract


13 Feb 2019

Cardiology and therapy, Volume 8, Issue 1, 13 2 2019, Pages 55-67 Plasma LDL-Cholesterol Level at Admission is Independently Associated with Infarct Size in Patients with ST-Segment Elevation Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention. Bodde MC, Hermans MPJ, Wolterbeek R, Cobbaert CM, van der Laarse A, Schalij MJ, Jukema JW. Abstract


30 Jan 2019

Cardiology and therapy, Volume 8, Issue 1, 30 5 2019, Pages 29-41 Growth Differentiation Factor-15 Levels at Admission Provide Incremental Prognostic Information on All-Cause Long-term Mortality in ST-Segment Elevation Myocardial Infarction Patients Treated with Primary Percutaneous Coronary Intervention. Bodde MC, Hermans MPJ, van der Laarse A, Mertens B, Romijn FPHTM, Schalij MJ, Cobbaert CM, Jukema JW. Abstract